Under Armour has fallen 22% in a single week to $5.34, yet short sellers are covering aggressively — the two signals are pulling in opposite directions, and the next earnings print on August 26 sits squarely in the middle.
The sharp drop in short interest is the standout move this week. Short interest fell nearly 18% on Tuesday alone, bringing the total to 23.8% of free float — still a very elevated level, but down from a range that had been stubbornly parked above 25% for most of July. The covering appears reactive to the price collapse rather than a vote of confidence: a stock down 9% in a session is precisely where forced covers happen. Cost to borrow, at 0.49%, has barely moved — well below crisis territory — and borrow availability has tightened meaningfully from around 103% two weeks ago to 55% now, meaning the lending pool is absorbing more demand even as some shorts exit. The ORTEX short score remains elevated at 73.4, ranking in the bottom 3rd percentile across the universe, signalling that aggregate short positioning is still extreme despite the recent unwind.
Options traders are not reading this as a bottom. The put/call ratio has climbed to 2.70, nearly touching its 52-week high of 2.72 and running almost two standard deviations above its 20-day average of 2.34. That is an unusual degree of downside demand even by UAA's own historically bearish options profile. The PCR has been elevated all year — it bottomed near 0.45 on a 52-week basis — but the spike over the past week to multi-year highs tells a specific story: with Q1 results out August 7 delivering an 8.3% single-day drop, traders are loading puts ahead of the August 26 print rather than fading the decline.
Street sentiment confirms the reluctance to buy. Barclays downgraded the stock to Underweight on August 11, keeping a $5.00 target essentially at current price. UBS, the lone bull in an otherwise cautious room, trimmed its Buy target from $10 to $9. Truist lifted its Hold target modestly to $6. The consensus sits at Hold with 18 analysts neutral and two explicitly negative — the mean target of $6.40 implies limited upside from $5.34, and the direction of travel on targets across the Street has been consistently downward since May. The bull case rests on sequential improvements in full-price realization and a new Sportstyle segment gaining traction; the bear case centres on debt levels, below-consensus FY27 guidance, and a turnaround timeline the market has repeatedly found longer than promised. EPS momentum scores rank in the bottom 10th–20th percentile of the universe, reflecting how sharply forward estimates have been revised.
One institutional angle deserves a mention. Fairfax Financial / Hamblin Watsa, already the largest holder at 15.4% of shares, bought nearly 1.2 million shares in May at prices around $4.95–$5.00 — near current levels. BlackRock has also been adding, picking up 12.5 million shares as recently as July 31. Neither move has arrested the decline. Founder Kevin Plank holds 12.9% and trimmed a nominal 236,000 shares in May, a small reduction but one worth tracking as execution pressure mounts. The stock's own earnings history offers a cautionary data point: both recent prints delivered one-day declines of 8–9%, with no evidence in the data of meaningful recovery in the days that followed.
The August 26 earnings report is now the only thing that matters — the question is whether the Street has finally reset expectations enough that UAA can clear the bar, or whether the combination of a 23% short float, a PCR at its 52-week high, and a Street full of reluctant Holds means any miss hits an unforgiving tape.
See the live data behind this article on ORTEX.
Open UAA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
